Related Experiment Video

Updated: May 11, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Targeting angiopoietin-2 signaling in cancer therapy

Zeynep Eroglu1, Cy A Stein, Sumanta K Pal

  • 1City of Hope Comprehensive Cancer Center, Department of Medical Oncology & Experimental Therapeutics, 1500 East Duarte Road, Duarte, CA 91010, USA.

Expert Opinion on Investigational Drugs
|April 30, 2013
PubMed
Abstract

Insights

Novel anti-angiogenic therapies targeting the Ang/Tie-2 pathway show promise for cancer treatment. Further development hinges on managing toxicity when combined with other therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Anti-angiogenic strategies are crucial in treating various cancers.
  • Current therapies like bevacizumab, sunitinib, and sorafenib target vascular endothelial growth factor receptor (VEGFR) signaling.
  • While effective in delaying progression, existing VEGFR inhibitors are not curative.

Purpose of the Study:

  • To review the clinical development of Ang/Tie-2 axis inhibitors.
  • To explore the potential of targeting the Ang/Tie-2 pathway for cancer therapy.
  • To examine combination strategies involving Ang/Tie-2 inhibitors.

Main Methods:

  • Review of clinical trial data for Ang/Tie-2 inhibitors.
  • Analysis of combination therapies with cytotoxic agents and other targeted drugs.
  • Evaluation of the Ang/Tie-2 signaling pathway's role in endothelial and perivascular cell interactions.

Main Results:

  • Several Ang/Tie-2 inhibitors have advanced to late-stage clinical trials (e.g., AMG-386, regorafenib).
  • Some agents are in early developmental stages (e.g., ARRY614, CEP-11981).
  • Data on combining Ang/Tie-2 inhibitors with other treatments are being gathered.

Conclusions:

  • The Ang/Tie-2 axis represents a novel target for anti-angiogenic cancer therapy.
  • Combination strategies may enhance efficacy but require careful toxicity assessment.
  • Ang/Tie-2 inhibitors could offer a promising avenue for future cancer treatment development if toxicity is managed.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...